C4 Therapeutics to Participate in Major Scientific Summit
C4 Therapeutics, Inc. (C4T), a pioneering clinical-stage biopharmaceutical entity, is making headlines for its upcoming participation in the 7th Annual Targeted Protein Degradation & Induced Proximity Summit. This significant event is set to energize discussions around advancements in targeted protein degradation science, attracting experts and industry leaders.
Insights from Company Leaders at the Event
The summit will take place from October 28-31, 2024, and will feature four leaders from C4 Therapeutics, who will contribute their expertise via oral presentations and panel discussions. These engagements are not just opportunities for knowledge sharing; they are platforms to demonstrate how C4T is advancing the field of targeted protein degradation, an area crucial to developing transformative therapies.
Panel Discussion: CEO Think Tank
On October 29, CEO Andrew Hirsch will lead a panel discussion titled "CEO Think Tank: A Strategic Look at Targeted Protein Degradation & Induced Proximity Field" at 9:30 am ET. This session promises to unveil strategic insights that could shape the direction of therapeutic innovations.
Oral Presentation on Kinetics-Based PKPD Modeling
Following this, Stew Fisher, the Chief Scientific Officer, will present an oral talk at 11:30 am ET on using kinetics-based PKPD modeling to optimize degraders, highlighting C4T's innovative approaches to drug development.
Key Clinical Findings to Be Shared
On October 30, attendees will gain access to initial clinical data from the ongoing trial of CFT1946, presented by Chief Medical Officer Len Reyno at 8:30 am ET. The information shared in these sessions could provide new perspectives on therapeutic possibilities.
Lessons from Strategic Partnerships
Additionally, Scott Boyle, the Chief Business Officer, will partake in two essential panel discussions at 4:10 pm and 4:55 pm ET, focusing on lessons learned from major strategic partnership deals for both platforms and assets. These discussions are particularly relevant as they reflect on C4T’s approach to collaboration and growth in the biopharmaceutical landscape.
About C4 Therapeutics
C4 Therapeutics is dedicated to realizing the potential of targeted protein degradation to create groundbreaking medicines. Its efforts in advancing oncology programs are complemented by its proprietary TORPEDO platform, specifically designed to streamline the creation and optimization of small-molecule drugs aimed at difficult-to-treat diseases. C4T's unique approach aims to harness the body's natural mechanisms for degrading harmful proteins, providing hope for improved outcomes in patients facing complex health challenges.
Contact Information
For inquiries, investors can reach out to Courtney Solberg, Senior Manager of Investor Relations, at CSolberg@c4therapeutics.com. Media inquiries should be directed to Loraine Spreen, Senior Director of Corporate Communications & Patient Advocacy, at LSpreen@c4therapeutics.com.
Frequently Asked Questions
What is C4 Therapeutics focusing on at the summit?
C4 Therapeutics is showcasing its innovations in targeted protein degradation and discussing strategies in clinical trials.
Who will represent C4 Therapeutics at the event?
The leadership team, including Andrew Hirsch, Stew Fisher, Len Reyno, and Scott Boyle, will make presentations and participate in discussions.
What is the significance of the TORPEDO platform?
The TORPEDO platform helps C4T design and optimize drugs, enhancing the development of targeted therapeutics.
How does C4 Therapeutics' approach benefit patients?
The company's methods focus on degrading disease-causing proteins, addressing challenges like drug resistance and improving patient outcomes.
Where can I find more details about the summit?
Details about the summit can be explored on the event's official website, providing overviews of the presented sessions.
